Literature DB >> 7870894

Antagonism of the morphine-induced Straub tail reaction by kappa-opioid receptor activation in mice.

M Narita1, T Suzuki, M Misawa, H Nagase.   

Abstract

The Straub tail reaction (STR) induced by intracerebroventricular injection (ICV) of morphine was significantly antagonized by beta-funaltrexamine (beta-FNA, mu antagonist), given intracerebroventricularly (ICV), but not naltrindole given ICV (NTI, delta antagonist) or SC norbinaltorphimine given subcutaneously (SC) (nor-BNI, kappa antagonist). When given either SC or ICV the kappa-agonist, U-50,488 H markedly suppressed the STR elicited by ICV morphine; these effects were reversed by nor-BNI. These results suggest that the activation of supraspinal kappa receptors can inhibit the ICV morphine-induced STR which results from activation of supraspinal mu receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870894     DOI: 10.1007/bf02246982

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse.

Authors:  T J HALEY; W G MCCORMICK
Journal:  Br J Pharmacol Chemother       Date:  1957-03

Review 3.  Kappa-opioid receptors and analgesia.

Authors:  M J Millan
Journal:  Trends Pharmacol Sci       Date:  1990-02       Impact factor: 14.819

4.  Dynorphin(1-13), a long-lasting inhibitor of opiate receptor binding in vitro.

Authors:  J Garzón; M F Jen; P Sánchez-Blázquez; N M Lee
Journal:  Life Sci       Date:  1982 Oct 18-25       Impact factor: 5.037

5.  Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist.

Authors:  P S Portoghese; M Sultana; A E Takemori
Journal:  Eur J Pharmacol       Date:  1988-01-27       Impact factor: 4.432

6.  A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.

Authors:  P S Portoghese; D L Larson; L M Sayre; D S Fries; A E Takemori
Journal:  J Med Chem       Date:  1980-03       Impact factor: 7.446

7.  Effect of centrally acting muscle relaxants on the morphine-induced Straub tail reaction in mice.

Authors:  T Kameyama; M Ukai
Journal:  Chem Pharm Bull (Tokyo)       Date:  1979-05       Impact factor: 1.645

8.  Opposite effects of mu and kappa opiates on the firing-rate of dopamine cells in the substantia nigra of the rat.

Authors:  J M Walker; L A Thompson; J Frascella; M W Friederich
Journal:  Eur J Pharmacol       Date:  1987-01-28       Impact factor: 4.432

9.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

10.  Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays.

Authors:  A E Takemori; B Y Ho; J S Naeseth; P S Portoghese
Journal:  J Pharmacol Exp Ther       Date:  1988-07       Impact factor: 4.030

View more
  3 in total

1.  Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.

Authors:  J Cory Kalvass; Candace L Graff; Gary M Pollack
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

2.  Straub tail reaction in mice treated with σ(1) receptor antagonist in combination with methamphetamine.

Authors:  Junichi Kitanaka; Nobue Kitanaka; F Scott Hall; George R Uhl; Koh-Ichi Tanaka; Nobuyoshi Nishiyama; Motohiko Takemura
Journal:  Brain Res       Date:  2012-09-08       Impact factor: 3.252

3.  Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation.

Authors:  S M Pearl; D W Johnson; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.